Superluminal Medicines, Inc., 'The Membrane Company' using generative biology, chemistry, and machine learning approaches to revolutionize the speed and accuracy of how medicines are created, announced the closing of a $120 million Series A funding round. RA Capital Management led the investment, with participation from existing investors Insight Partners, NVentures (NVIDIA's venture capital arm), and Gaingels. New investors Catalio Capital Management, Eli Lilly and Company, and Cooley LLP joined in the financing, and Diamantis Xylas, MD of Catalio joined the Board of Directors.